$ABBV (AbbVie Inc.)

$ABBV {{ '2017-05-15T10:56:24+0000' | timeago}} • Announcement

$ABBV announced results from an analysis of data pooled from three Phase 3 studies evaluating Imbruvica (ibrutinib) use in patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). CLL is a type of cancer that starts from cells that become certain white blood cells in the bone marrow.

$ABBV {{ '2017-10-18T16:05:30+0000' | timeago}} • Announcement

$ABBV and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced that they have entered an immuno-oncology research collaboration.

$ABBV {{ '2017-09-27T12:14:25+0000' | timeago}} • Announcement

$ABBV announced that the Japanese Ministry of Health, Labor and Welfare has approved MAVIRET, a once-daily, treatment for adults with chronic hepatitis C virus infection. The treatment was also recently granted marketing authorization by the European Commission and approved by the US FDA.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$ABBV {{ '2017-08-04T18:18:09+0000' | timeago}} • Announcement

The FDA approved $ABBV’s Mavyret to treat adults with chronic hepatitis C virus across all major genotypes (GT1-6). It is an 8-week treatment for patients without cirrhosis and who are new to treatment. Up to 95% of HCV patients in the U.S. may be eligible for the new cure, including those with compensated cirrhosis and limited treatment options.

$ABBV {{ '2017-08-03T13:59:03+0000' | timeago}} • Announcement

$ABBV got the FDA nod for Imbruvica (Ibrutinib) used for treating adult patients with chronic graft-versus-host-disease after failure of one or more treatment. This is the first drug approved to treat the disease, a serious fallout of stem cell or bone marrow transplant. It was co-developed by Pharmacyclics, an AbbVie company, and Janssen Biotech.

$ENTA {{ '2017-07-28T21:01:27+0000' | timeago}} • Announcement

$ENTA said the European Commission (EC) has granted $ABBV marketing authorization for Maviret (glecaprevir/pibrentasvir) for treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. $ENTA expects to receive a $25MM milestone payment from $ABBV.

$ABBV {{ '2017-07-28T15:50:59+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ABBV {{ '2017-07-28T12:13:15+0000' | timeago}} • Announcement

Global HUMIRA sales for $ABBV rose 13.7% in 2Q17, while Global IMBRUVICA net revenues jumped 42.6%. The gross margin ratio in the second quarter was 78.0%, with adjusted gross margin ratio at 82.3%.

$ABBV {{ '2017-07-28T12:04:31+0000' | timeago}} • Announcement

While posting 2Q17 results, $ABBV confirmed its GAAP diluted EPS guidance for FY17 of $4.55-4.65. AbbVie expects to deliver adjusted diluted EPS of $5.44 to $5.54, representing growth of 13.% at the mid-point.

$ABBV {{ '2017-07-28T12:02:43+0000' | timeago}} • Announcement

With the biopharma giant's net revenues up 7.6% to $6.9Bil in 2Q17, $ABBV's net earnings soared 19% to $1.9Bil or $1.19 per share.  Adjusted diluted EPS was $1.42, up 12.7% in the quarter.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABBV {{ '2017-06-23T16:10:50+0000' | timeago}} • Announcement

$ABBV said Maviret, if approved, will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV. The European Commission will now review the CHMP opinion and a final decision is expected in 3Q17.

$ABBV {{ '2017-06-23T16:10:05+0000' | timeago}} • Announcement

$ABBV said the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending marketing authorization of Maviret, an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection.

$ABBV {{ '2017-06-23T11:59:17+0000' | timeago}} • Announcement

Pharma company $ABBV said the pivotal phase-2 study on its leukaemia drug Venlcyxto, a first-in-class oral B-cell lymphoma-2 inhibitor, yielded encouraging results. The results will be presented at the European Hematology Association meeting. The study was conducted on patients with CLL and 17p deletion who were refractory to prior treatments.

$ABBV {{ '2017-06-23T10:44:35+0000' | timeago}} • Announcement

$ABBV's BoD declared  a quarterly cash dividend of $0.64 per share. The dividend is payable on Aug. 15, 2017, to stockholders of record at the close of business on July 14, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$ABBV {{ '2017-06-13T14:49:59+0000' | timeago}} • Announcement

$ABBV and Principia Biopharma entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.

$ABBV {{ '2017-06-12T11:26:02+0000' | timeago}} • Announcement

$ABBV will present data from multiple clinical trials evaluating its leukaemia drug venetoclax at the 22nd European Hematology Association Annual Congress to be held in Madrid. Data will be presented from 15 studies across common hematologic malignancies, including chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
OMER (Omeros Corporation)
Tuesday, August 8 2017 - 8:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, August 7 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, July 27 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm

AlphaGraphics you may like